Estudio de la estructura factorial de la escala de calidad de vida FACIT-P para los pacientes con cáncer de próstata

Información del artículo

Resumen

Objetivo

Realizar el análisis de la estructura de dominios de la escala FACIT-P (4.a versión), instrumento diseñado para medir el constructo de calidad de vida en pacientes con cáncer de próstata (CP).

Métodos

El método seleccionado para delimitar las variables latentes fue el de máxima verosimilitud. La estructura factorial escogida para buscar variables latentes partió de una rotación ortogonal tipo varimax.

Resultados

En los pacientes evaluados, más de la mitad procedían de Bogotá, la gran mayoría solo había cursado primaria, y de acuerdo con la escala Gleason, una cuarta parte presentaba un CP de grado intermedio o alto. Los dominios incluidos fueron: 1. aspectos que representan dolor y molestias; 2. elementos relacionados con autonomía y capacidad de desempeño; 3. aspectos de red social, familiar y satisfacción; 4. elementos relacionados con depresión y ansiedad; 5. síntomas específicos del cáncer de próstata.

Conclusiones

La estructura de dominios que muestra el instrumento en pacientes colombianos con CP mostró una organización de variables latentes plausible, y similares al constructo de la escala original.

Palabras clave:

Calidad de vida

neoplasias de la próstata

psicometría

cuestionarios

Abstract

Objective

To analyze the dominion structure of the FACIT-P scale (4th version), an instrument designed to measure the quality of life construct in prostate cancer (PC) patients.

Methods

The selected method sought to achieve greatest possible verisimilitude for discrimination of latent variables. The factorial structure chosen to single out latent variables was based upon varimax orthogonal rotation.

Results

More than half the number of patients evaluated came from Bogota; a large majority had only primary school education; on the Gleason scale, one fourth suffered from intermediate or high grade PC. Dominions included aspects related to: 1. Pain and discomfort; 2. Independence and performance capacity; 3. Social network, family life and contentment; 4. Depression and anxiety; 5. Specific symptoms related to prostate cancer.

Conclusions

The dominion structure produced by the instrument among Colombian PC patients revealed a plausible latent variable organization that resembled the original scale construct.

Key words:

Quality of life

prostatic neoplasms/drug therapy

prostatic neoplasms/psychology

psychometrics

questionnaires

El Texto completo está disponible en PDF

Referencias

[1.]

M.F. Leitzmann, S. Rohrmann.

Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates.

Clin Epidemiol, 4 (2012), pp. 1-11

http://dx.doi.org/10.2147/CLEP.S31104 | Medline

[2.]

C. Maringe, P. Mangtani, B. Rachet, D.A. Leon, M.P. Coleman, I. Dos Santos Silva.

Cancer incidence in South Asian migrants to England, 1986–2004: Unraveling ethnic from socioeconomic differentials.

Int J Cancer, (2012),

[3.]

M. Outzen, K. Brasso, N. Martinussen, J. Christensen, A. Tjonneland, S. Friis, et al.

Prostate cancer in Denmark 1978–2009 - trends in incidence and mortality.

Acta Oncol, (2012),

[4.]

K. Shafique, R. Oliphant, D.S. Morrison.

The impact of socio-economic circumstances on overall and grade-specific prostate cancer incidence: a population-based study.

Br J Cancer, 107 (2012), pp. 575-582

http://dx.doi.org/10.1038/bjc.2012.289 | Medline

[5.]

E. Scosyrev, G. Wu, S. Mohile, E.M. Messing.

Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation : Analysis of trends over time.

Cancer, (2012),

[6.]

Ferlay J, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0. Lyon, France [internet]. 2008 [citado: 17 de junio de 2011]. Disponible en: http://globocan.iarc.fr.

[7.]

M. Piñeros, J. Ferlay, R. Murillo.

Incidencia estimada y mortalidad por cáncer en Colombia: 1995–1999.

Imprenta Nacional, (2005),

[8.]

S.M. Hunt.

Cross-cultural comparability of quality of life measures.

Drug Inf J, 27 (1993), pp. 395-400

[9.]

M.E. O’Rourke.

Choose wisely: therapeutic decisions and quality of life in patients with prostate cancer.

Clin J Oncol Nurs, 11 (2007), pp. 401-408

http://dx.doi.org/10.1188/07.CJON.401-408 | Medline

[10.]

P. Esper, F. Mo, G. Chodak, M. Sinner, D. Cella, K.J. Pienta.

Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument.

Urology, 50 (1997), pp. 920-928

http://dx.doi.org/10.1016/S0090-4295(97)00459-7 | Medline

[11.]

J.E. Batista-Miranda, C. Sevilla-Cecilia, R. Torrubia, M. Musquera, J. Huguet-Perez, X. Ponce de Leon, et al.

Quality of life in prostate cancer patients and controls: psychometric validation of the FACTP-4 in Spanish, and relation to urinary symptoms.

Arch Españ Urol, 56 (2003), pp. 447-454

Medline

[12.]

J.H. Hong, S.S. Jeon, H.M. Lee, Y.H. Choi, S. Kim, H.Y. Choi.

The Functional Assessment of Cancer Therapy-Prostate (FACTP) scales in men with prostate cancer: reliability and validity of the Korean version.

J Kor Med Sci, 21 (2006), pp. 295-299

[13.]

K. Webster, D. Cella, K. Yost.

The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation.

Health Qual Life Out, 1 (2003), pp. 79

[14.]

F. Haseen, L.J. Murray, R.F. O’Neill, J.M. O'Sullivan, M.M. Cantwell.

A randomised controlled trial to evaluate the efficacy of a 6 month dietary and physical activity intervention for prostate cancer patients receiving androgen deprivation therapy.

Trials, 11 (2010), pp. 86

http://dx.doi.org/10.1186/1745-6215-11-86 | Medline

[15.]

C.J. Nelson, M.I. Weinberger, E. Balk, J. Holland, W. Breitbart, A.J. Roth.

The chronology of distress, anxiety, and depression in older prostate cancer patients.

Oncologist, 14 (2009), pp. 891-899

http://dx.doi.org/10.1634/theoncologist.2009-0059 | Medline

[16.]

M. Sia, G. Rodríguez, C. Menard, A. Bayley, R. Bristow, P. Chung, et al.

Treatment-related toxicity and symptom-related bother following postoperative radiotherapy for prostate cancer.

Can Urol Assoc J, 4 (2010), pp. 105-111

Medline

[17.]

I. Syndikus, R.C. Morgan, M.R. Sydes, J.D. Graham, D.P. Dearnaley.

Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397).

Int J Rad Oncol, 77 (2010), pp. 773-783

[18.]

P. Warde, M. Mason, K. Ding, P. Kirkbride, M. Brundage, R. Cowan, et al.

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

Lancet, 378 (2011), pp. 2104-2111

http://dx.doi.org/10.1016/S0140-6736(11)61095-7 | Medline

[19.]

M.S. Litwin, R.D. Hays, A. Fink, P.A. Ganz, B. Leake, R.H. Brook.

The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure.

Med Care, 36 (1998), pp. 1002-1012

Medline

[20.]

M.R. Stockler, D. Osoba, P. Goodwin, P. Corey, I.F. Tannock.

Responsiveness to change in health-related quality of life in a randomized clinical trial: a comparison of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) with analogous scales from the EORTC QLQ-C30 and a trial specific module. European Organization for Research and Treatment of Cancer.

J Clin Epidemiol, 51 (1998), pp. 137-145

Medline

[21.]

G. Van Andel, A. Bottomley, S.D. Fossa, F. Efficace, C. Coens, S. Guerif, et al.

An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer.

Eur J Cancer, 44 (2008), pp. 2418-2424

http://dx.doi.org/10.1016/j.ejca.2008.07.030 | Medline

[22.]

B. Rosner.

Fundamentals of Biostatistics.

7th, Cengage Learning, (2011),

[23.]

M.A. Pett, N.R. Lackey, J.J. Sullivan.

Making sense of factor analysis. The use of factor analysis for instrument development in health care research.

Sage Pub, (2003),

[24.]

H.F. Kaiser.